Navigation Links
Fate Therapeutics Closes $30 Million Series B Financing
Date:11/16/2009

ncing, we have raised the necessary funds to build on the pioneering research and foundational intellectual property of our scientific founders for human cell reprogramming and to enable the commercialization of our pharmaceutical grade iPSC technology."

About OVP Venture Partners

For 26 years, OVP Venture Partners has led the drive into new, high-growth technology markets in the Pacific Northwest. OVP makes early stage investments in cleantech, digital biology and information technology. The firms' record of 52 liquidity events - including 22 IPOs - leads the region. OVP has over $750 million in capital under management and is currently investing its seventh fund. The firm has offices in Seattle, WA and Portland, OR. More information on the partnership is available at www.ovp.com.

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company is currently conducting a Phase 1b clinical trial of FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies. In addition, Fate Therapeutics and Stemgent have formed an alliance - CATALYST - a collaborative program to provide its members with first access to the most advanced iPSC technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit www.fatetherapeutics.
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
2. Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
3. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
4. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
5. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
6. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
7. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
8. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
9. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
(Date:1/14/2014)... 14, 2014 Independent publisher Bitingduck Press, ... Montreal, Canada, has big ideas for 2014 in production ... goals are to produce high-quality, low-cost, DRM-free ebooks and ... businesses. , The first major development will be ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Caffeine Test Strips, to Know for Sure, Studies show that ... ... levels of caffeine, MONROVIA, Calif., Nov. 12 Ever wonder whether ... for sure,with new D+CAF, the first ever do-it-yourself caffeine test strip from,Silver ...
... MaxCyte, Inc.,the pioneer in scalable, high performance ... a live discussion with industry experts on the,challenges ... discussion is open to the industry and will ... 2:00-3:00EST., One of the respected industry experts ...
... Implementation Issues and Recommendations, BETHLEHEM, Pa., ... of Clinical Value Marketing, Infusion Systems Division ... Services for B. Braun Medical,Inc. (B. Braun), ... and services,recently represented B. Braun at the ...
Cached Biology Technology:Is Your Decaf Really Decaf? 2MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 3
(Date:7/9/2014)... bladders of healthy women differ from bacteria in ... to researchers from Loyola University Chicago Stritch School ... 9, 2014, in the American Society for Microbiology,s ... communities may play a role in female urinary ... common, yet poorly understood, condition with symptoms similar ...
(Date:7/9/2014)... Centre (CNIO) have discovered that NANOG, an essential gene ... stratified epitheliathose that form part of the epidermis of ... adult organisms. According to the conclusions of the study, ... factor could also play a role in the formation ... and skin. , The pluripotency factor NANOG is active ...
(Date:7/9/2014)... studying critically ill children with traumatic injuries have ... are likely to develop a hospital-acquired infection. The ... and published online in June in the journal ... efforts that could lead to the clinical implementation ... prevent or reverse immune system damage following critical ...
Breaking Biology News(10 mins):CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical ... and Prevention (CDC) have reported the identification of ... range of influenza A viruses, including avian influenza ... some seasonal influenza viruses. These antibodies have the ...
... International, Inc. (OTC Bulletin Board: BKYI), a leader in ... today that it will participate in Imperial Capital,s Homeland ... of March. Additional details regarding BIO-key,s participation at ... , Imperial Capital,s ...
... Permanently Disposes Magnetically Recorded Data to Help QSGI,s ... Calif., Feb. 18 Fujitsu Computer Products of ... products including hard disk drives, peripherals and biometric ... using the Fujitsu Mag EraSURE degaussing ...
Cached Biology News:Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 2Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 3BIO-key(R) Announces Conference Schedule 2QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 2QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 3QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 4QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 5
... The dsRNA Marker consists of ten ... 200, 300, 400, 500 and 1,000 base ... size marker for determinating sizes of double-stranded ... in the dsRNA Marker is adjusted to ...
... size markers are a mixture of Strep•Tag® ... 100 kDa. The markers provide precise size ... staining with Coomassie blue. Because each of ... the markers can also be detected by ...
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
... V, is used for agitation and mixing applications ... and destaining of gels and blots, and Southern ... rpm) and can handle a maximum load of ... 29 x 21 cm platforms covered with nonslip ...
Biology Products: